Clinical outcomes and healthcare costs among people entering a safer opioid supply program in Ontario
Gomes T, Kolla G, McCormack D, Sereda A, Kitchen S, Antoniou T. CMAJ. 2022; 194(36):E1233-42. Epub 2022 Sep 19.
Publications
The burden of cancer among people living with HIV in Ontario, Canada, 1997-2020: a retrospective population-based cohort study using administrative health data
Nicolau IA, Antoniou T, Brooks JD, Moineddin R, Cooper C, Cotterchio M, Gillis JL, Kendall CE, Kroch AE, Lindsay JD, Price C, Salters K, Smieja M, Burchell AN. CMAJ Open. 2022; 10(3):E666-74. Epub 2022 Jul 19.
Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: a population-based study
Antoniou T, Men S, Tadrous M, Leece P, Munro C, Gomes T. Drug Alcohol Depend. 2022; 236:109473. Epub 2022 Apr 26.
Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis
Garg R, Kitchen SA, Men S, Campbell TJ, Bozinoff N, Tadrous M, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. Drug Alcohol Depend. 2022; 236:109459. Epub 2022 Apr 14.
The risk of ventricular dysrhythmia or sudden death in patients receiving serotonin reuptake inhibitors with methadone: a population-based study
Antoniou T, McCormack D, Tadrous M, Juurlink DN, Gomes T. Front Pharmacol. 2022; 13:861953. Epub 2022 Mar 11.
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study
Gomes T, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, Campbell T, Paterson JM, Mamdani M, Sproule B. Addiction. 2022; 117(7):1972-81. Epub 2022 Mar 8.
Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: a population-based time-series analysis
Kitchen SA, Campbell TJ, Men S, Bozinoff N, Tadrous M, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. Int J Drug Policy. 2022; 103:103644. Epub 2022 Mar 1.
Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation
Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, Tadrous M, Munro C, Antoniou T, Werb D, Wyman J. JAMA. 2022; 327(9):846-55. Epub 2022 Mar 1.
Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada
Young S, Koll G, McCormack D, Campbell T, Leece P, Strike C, Srivastava A, Antoniou T, Bayoumi AM, Gomes T. Int J Drug Policy. 2022; 102:103601. Epub 2022 Feb 3.
The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis
Boone CG, Antoniou T, Juurlink DN, von den Baumen TR, Kitchen SA, Richards GC, Tadrous M, Gomes T. CMAJ Open. 2021; 9(4):E1181-6. Epub 2021 Dec 14.